2937 related articles for article (PubMed ID: 26898616)
1. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer.
Tan CS; Cho BC; Soo RA
Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
3. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
4. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
5. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer?
Sun JM; Park K
Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680
[TBL] [Abstract][Full Text] [Related]
6. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
7. Emerging treatment for advanced lung cancer with EGFR mutation.
Inal C; Yilmaz E; Piperdi B; Perez-Soler R; Cheng H
Expert Opin Emerg Drugs; 2015; 20(4):597-612. PubMed ID: 26153235
[TBL] [Abstract][Full Text] [Related]
8. Clinical approaches to treat patients with non-small cell lung cancer and epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance.
Tartarone A; Lerose R
Ther Adv Respir Dis; 2015 Oct; 9(5):242-50. PubMed ID: 26016841
[TBL] [Abstract][Full Text] [Related]
9. Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies.
Lim SM; Syn NL; Cho BC; Soo RA
Cancer Treat Rev; 2018 Apr; 65():1-10. PubMed ID: 29477930
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy.
Kanda S; Horinouchi H; Fujiwara Y; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Kubota K; Tamura T; Ohe Y
Lung Cancer; 2015 Sep; 89(3):287-93. PubMed ID: 26169499
[TBL] [Abstract][Full Text] [Related]
11. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
12. Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.
Patel H; Pawara R; Ansari A; Surana S
Eur J Med Chem; 2017 Dec; 142():32-47. PubMed ID: 28526474
[TBL] [Abstract][Full Text] [Related]
13. Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.
Noda S; Kanda S
Expert Rev Respir Med; 2016; 10(5):547-56. PubMed ID: 26959310
[TBL] [Abstract][Full Text] [Related]
14. Epidermal Growth Factor Receptor-Mutant Lung Cancer: New Drugs, New Resistance Mechanisms, and Future Treatment Options.
Piotrowska Z; Sequist LV
Cancer J; 2015; 21(5):371-7. PubMed ID: 26389761
[TBL] [Abstract][Full Text] [Related]
15. Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.
Lee CK; Kim S; Lee JS; Lee JE; Kim SM; Yang IS; Kim HR; Lee JH; Kim S; Cho BC
Lung Cancer; 2017 Nov; 113():106-114. PubMed ID: 29110836
[TBL] [Abstract][Full Text] [Related]
16. EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance.
Wang S; Song Y; Liu D
Cancer Lett; 2017 Jan; 385():51-54. PubMed ID: 27840244
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Choi YL; Ahn JS; Park K
Lung Cancer; 2013 Nov; 82(2):294-8. PubMed ID: 24035188
[TBL] [Abstract][Full Text] [Related]
18. Impact of clinical parameters and systemic inflammatory status on epidermal growth factor receptor-mutant non-small cell lung cancer patients readministration with epidermal growth factor receptor tyrosine kinase inhibitors.
Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
BMC Cancer; 2016 Nov; 16(1):868. PubMed ID: 27821111
[TBL] [Abstract][Full Text] [Related]
19. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
20. Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress.
Castellanos EH; Horn L
Curr Treat Options Oncol; 2015 Oct; 16(10):51. PubMed ID: 26364032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]